http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 13 Mar 2026 07:46:03 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+files+Hong+Kong+patent+for+depression+therapy+combo/26156476.html <p>Clearmind Medicine Inc. (NASDAQ: CMND) filed a patent application in Hong Kong for a combination therapy to treat major depressive disorder, the company announced.</p><p>The treatment combines Clearmind's 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), sourced through a partnership with NeuroThera Labs Inc. (TSXV: NTLX), a subsidiary of SciSparc Ltd. (NASDAQ: SPRC).</p><p>The patent application was filed with Hong Kong's Intellectual Property Department for what the company describes as a non-hallucinogenic approach to treating depression. The therapy targets major depressive disorder, which affects more than 332 million people globally according to the company.</p><p>Clearmind is a clinical-stage biotech company focused on developing neuroplastogen-derived therapeutics. The http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+files+Hong+Kong+patent+for+depression+therapy+combo/26156476.html Fri, 13 Mar 2026 07:46:03 -0400 CMND CWY0 NTLX SPRC http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+files+Hong+Kong+patent+for+depression+therapy+combo/26156476.html <p>Clearmind Medicine Inc. (NASDAQ: CMND) filed a patent application in Hong Kong for a combination therapy to treat major depressive disorder, the company announced.</p><p>The treatment combines Clearmind's 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), sourced through a partnership with NeuroThera Labs Inc. (TSXV: NTLX), a subsidiary of SciSparc Ltd. (NASDAQ: SPRC).</p><p>The patent application was filed with Hong Kong's Intellectual Property Department for what the company describes as a non-hallucinogenic approach to treating depression. The therapy targets major depressive disorder, which affects more than 332 million people globally according to the company.</p><p>Clearmind is a clinical-stage biotech company focused on developing neuroplastogen-derived therapeutics. The http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+files+Hong+Kong+patent+for+depression+therapy+combo/26156476.html Fri, 13 Mar 2026 07:46:03 -0400 CMND CWY0 NTLX SPRC http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+files+Hong+Kong+patent+for+depression+therapy+combo/26156476.html <p>Clearmind Medicine Inc. (NASDAQ: CMND) filed a patent application in Hong Kong for a combination therapy to treat major depressive disorder, the company announced.</p><p>The treatment combines Clearmind's 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), sourced through a partnership with NeuroThera Labs Inc. (TSXV: NTLX), a subsidiary of SciSparc Ltd. (NASDAQ: SPRC).</p><p>The patent application was filed with Hong Kong's Intellectual Property Department for what the company describes as a non-hallucinogenic approach to treating depression. The therapy targets major depressive disorder, which affects more than 332 million people globally according to the company.</p><p>Clearmind is a clinical-stage biotech company focused on developing neuroplastogen-derived therapeutics. The http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+files+Hong+Kong+patent+for+depression+therapy+combo/26156476.html Fri, 13 Mar 2026 07:46:03 -0400 CMND CWY0 NTLX SPRC http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+files+Hong+Kong+patent+for+depression+therapy+combo/26156476.html <p>Clearmind Medicine Inc. (NASDAQ: CMND) filed a patent application in Hong Kong for a combination therapy to treat major depressive disorder, the company announced.</p><p>The treatment combines Clearmind's 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), sourced through a partnership with NeuroThera Labs Inc. (TSXV: NTLX), a subsidiary of SciSparc Ltd. (NASDAQ: SPRC).</p><p>The patent application was filed with Hong Kong's Intellectual Property Department for what the company describes as a non-hallucinogenic approach to treating depression. The therapy targets major depressive disorder, which affects more than 332 million people globally according to the company.</p><p>Clearmind is a clinical-stage biotech company focused on developing neuroplastogen-derived therapeutics. The http://www.streetinsider.com/Corporate+News/Clearmind+Medicine+files+Hong+Kong+patent+for+depression+therapy+combo/26156476.html Fri, 13 Mar 2026 07:46:03 -0400 CMND CWY0 NTLX SPRC http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html <p><i>Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030</i></p> <p>Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat major depressive disorder (MDD).</p> <p>This http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html Fri, 13 Mar 2026 07:45:00 -0400 CMND CWY0 NTLX O.06196855 O.40363429 O.50488485 SPRC http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html <p><i>Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030</i></p> <p>Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat major depressive disorder (MDD).</p> <p>This http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html Fri, 13 Mar 2026 07:45:00 -0400 CMND CWY0 NTLX O.06196855 O.40363429 O.50488485 SPRC http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html <p><i>Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030</i></p> <p>Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat major depressive disorder (MDD).</p> <p>This http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html Fri, 13 Mar 2026 07:45:00 -0400 CMND CWY0 NTLX O.06196855 O.40363429 O.50488485 SPRC http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html <p><i>Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030</i></p> <p>Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat major depressive disorder (MDD).</p> <p>This http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html Fri, 13 Mar 2026 07:45:00 -0400 CMND CWY0 NTLX O.06196855 O.40363429 O.50488485 SPRC http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html <p><i>Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030</i></p> <p>Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat major depressive disorder (MDD).</p> <p>This http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html Fri, 13 Mar 2026 07:45:00 -0400 CMND CWY0 NTLX O.06196855 O.40363429 O.50488485 SPRC http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html <p><i>Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030</i></p> <p>Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat major depressive disorder (MDD).</p> <p>This http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html Fri, 13 Mar 2026 07:45:00 -0400 CMND CWY0 NTLX O.06196855 O.40363429 O.50488485 SPRC http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html <p><i>Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030</i></p> <p>Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat major depressive disorder (MDD).</p> <p>This http://www.streetinsider.com/Press+Releases/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html Fri, 13 Mar 2026 07:45:00 -0400 CMND CWY0 NTLX O.06196855 O.40363429 O.50488485 SPRC http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html <p><i>Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030</i></p> <p>Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat major depressive disorder (MDD).</p> <p>This http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html Fri, 13 Mar 2026 07:45:00 -0400 CMND CWY0 NTLX O.06196855 O.40363429 O.50488485 SPRC http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html <p><i>Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030</i></p> <p>Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat major depressive disorder (MDD).</p> <p>This http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html Fri, 13 Mar 2026 07:45:00 -0400 CMND CWY0 NTLX O.06196855 O.40363429 O.50488485 SPRC http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html <p><i>Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030</i></p> <p>Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat major depressive disorder (MDD).</p> <p>This http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html Fri, 13 Mar 2026 07:45:00 -0400 CMND CWY0 NTLX O.06196855 O.40363429 O.50488485 SPRC http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html <p><i>Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030</i></p> <p>Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat major depressive disorder (MDD).</p> <p>This http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html Fri, 13 Mar 2026 07:45:00 -0400 CMND CWY0 NTLX O.06196855 O.40363429 O.50488485 SPRC http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html <p><i>Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030</i></p> <p>Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat major depressive disorder (MDD).</p> <p>This http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html Fri, 13 Mar 2026 07:45:00 -0400 CMND CWY0 NTLX O.06196855 O.40363429 O.50488485 SPRC http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html <p><i>Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030</i></p> <p>Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat major depressive disorder (MDD).</p> <p>This http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html Fri, 13 Mar 2026 07:45:00 -0400 CMND CWY0 NTLX O.06196855 O.40363429 O.50488485 SPRC http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html <p><i>Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030</i></p> <p>Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation,  neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application with the Intellectual Property Department (IPD) in Hong Kong, for am innovative combination therapy designed to treat major depressive disorder (MDD).</p> <p>This http://www.streetinsider.com/Globe+Newswire/Clearmind+Medicine+Announces+Hong+Kong+Patent+Filing+for+Depression+Therapy/26156474.html Fri, 13 Mar 2026 07:45:00 -0400 CMND CWY0 NTLX O.06196855 O.40363429 O.50488485 SPRC